Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival - Wikidata - wikimedia - TriplyDB

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

http://www.wikidata.org/entity/Q34918948

about

Double-Hit Lymphoma: Practicing in a Data-Limited Setting.Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Management of Patients with MYC-Altered Lymphomas.Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type.Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.Double-Hit Large B Cell Lymphoma.Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

P2860

Q31056413-5F9E65FC-D5F7-4EA7-B4B2-39288FDFA0EB Q33670880-FFC59B2C-02AA-464F-97AB-9C81AD8700B2 Q35960027-091115CF-D07D-49F8-96AE-29711F317BE5 Q36799405-6374363C-B7A8-44AC-B415-665A5C69C9AA Q37437423-70C5DBA0-FAF9-4783-8B47-3DF07C86ADB5 Q37445933-D7ECB6CB-1D39-490A-8921-79C3E81B454F Q37738081-469D9168-7443-4CB9-A192-C6D00E485DA7 Q38376595-2D01DBA2-AB37-44F2-A685-0FA729E87E8E Q44793052-28910A57-66B6-47A8-A7B7-9FA35421F053 Q45304558-FDA50E6B-D1A9-4B12-8E04-A85A0BF5137C Q47563827-BDC8B125-B104-4182-8969-658B4D061735

P2860

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

http://www.wikidata.org/entity/Q34918948

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Complete response to induction ...... nged progression-free survival

@ast

Complete response to induction ...... nged progression-free survival

@en

Complete response to induction ...... nged progression-free survival

@nl

type

label

Complete response to induction ...... nged progression-free survival

@ast

Complete response to induction ...... nged progression-free survival

@en

Complete response to induction ...... nged progression-free survival

@nl

prefLabel

Complete response to induction ...... nged progression-free survival

@ast

Complete response to induction ...... nged progression-free survival

@en

Complete response to induction ...... nged progression-free survival

@nl

P1433

Q34918948-73E6749A-5F4D-45B8-B22D-718885465D01

P1476

Q34918948-DC1D3248-3FFB-4437-AE0F-C21E1862C812

P2093

Q34918948-01FAB8B2-4322-4F54-898C-16204ACB3220

Q34918948-0B3CD5C7-0F5B-4AEA-9F52-0E4F7776CF18

Q34918948-1C3AC70B-D231-40AC-998A-57D6F3BCD3A7

Q34918948-20BF1ADF-A86F-49AD-B027-E92E63FFFA25

Q34918948-348129E9-3ACD-48F1-9313-DB06FF281935

Q34918948-4DAB544C-9E25-4C13-8B43-4E21D5625AEB

Q34918948-51408CE0-73E7-4573-B6E9-241F0A8EF65A

Q34918948-6EA75702-6334-452F-A74F-668B7DC6055B

Q34918948-7B80BC1F-AA05-497D-BB92-5E814DF3EE55

Q34918948-98E1EF12-E2DB-4C13-937D-224110F53F1C

P2860

Q34918948-23A149CB-1D94-405D-B6D2-5ABD1F1BEA5F

Q34918948-31155D60-C193-491F-B6F9-94A9150513B7

Q34918948-38FD2600-4D93-49EE-8019-12ED9BAF2A97

Q34918948-53A5BB7B-87F5-4BA4-9C59-F981DA683FBB

Q34918948-568EDDE6-E75D-44D5-B618-4100B7338A73

Q34918948-8202553D-6934-4B81-9041-CAE743A41623

Q34918948-84360654-5182-4A07-96C2-CB87755E6F5D

Q34918948-9462609A-6CB8-42C9-A7D3-65458B765705

Q34918948-9F96C304-9834-4FF8-8F7D-F961808A2EFE

Q34918948-A4BA9417-ED7B-4EF7-9E7F-55C0FF1C76E9

P304

Q34918948-E3F1A29B-B65C-41E2-B023-B6E3464564C0

P31

Q34918948-9A4449B8-F16B-43C4-9DD9-3A3F0E35938B

P356

Q34918948-93CD6EC2-60C2-47FC-B4C0-FD64E3A90A87

P407

Q34918948-6446F223-C4D2-4453-AAE4-B7D21935CDA6

P433

Q34918948-71DFE567-EAD1-4FEB-9BF9-6963A567A97D

P478

Q34918948-EBA78344-623E-438F-943F-9B67B3DF491F

P50

Q34918948-B0F38FC4-8757-4C96-B74F-035AFA4BF186

P577

Q34918948-227EF4FE-9267-42E5-9BD8-19DF60D0F1C6

P5875

Q34918948-35B24A7D-EAD4-4D34-B4AD-61C37EA56854

P698

Q34918948-094A96A3-99A8-4838-AFE6-E71C38ECEF7A

P932

Q34918948-F4749EEB-0C2C-4399-B9C0-B63BDB18CAE5

P356

P1433

P1476

Complete response to induction ...... nged progression-free survival

@en

P2093

Beth A Christian

http://www.w3.org/2001/XMLSchema#string

Gerard Lozanski

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Jones

http://www.w3.org/2001/XMLSchema#string

Jessica A Hemminger

http://www.w3.org/2001/XMLSchema#string

Jonathon B Cohen

http://www.w3.org/2001/XMLSchema#string

Joseph M Flynn

http://www.w3.org/2001/XMLSchema#string

Kami J Maddocks

http://www.w3.org/2001/XMLSchema#string

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

Nathan C Hall

http://www.w3.org/2001/XMLSchema#string

Pierluigi Porcu

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.

P304

1677-1685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.28642

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260431082

http://www.w3.org/2001/XMLSchema#string

P698

24578014

http://www.w3.org/2001/XMLSchema#string

P932

4291121

http://www.w3.org/2001/XMLSchema#string